Title

Pharmacokinetics of tulathromycin on plasma and semen of beef bulls

Authors

Juan E. Romano, Large Animal Clinical Sciences. College of Veterinary Medicine & Biomedical Sciences.Texas A&M University. College Station, TX, 77843-4475, USA. Electronic address: juanromano@live.com.
Andrea Barbarossa, Department of Veterinary Medical Sciences, University of Bologna, 40064, Ozzano dell'Emilia. Bologna, Italy; Health Sciences and Technologies-Interdepartmental Centre for Industrial Research (CIRI-SDV), University of Bologna, 40064, Ozzano dell'Emilia, Bologna, Italy.
Giampiero Pagliuca, Department of Veterinary Medical Sciences, University of Bologna, 40064, Ozzano dell'Emilia. Bologna, Italy; Health Sciences and Technologies-Interdepartmental Centre for Industrial Research (CIRI-SDV), University of Bologna, 40064, Ozzano dell'Emilia, Bologna, Italy.
Graciela B. Villadóniga, St. Joseph Regional Health Center, Pediatric Services, Bryan, TX, USA.
Teresa Gazzotti, Department of Veterinary Medical Sciences, University of Bologna, 40064, Ozzano dell'Emilia. Bologna, Italy; Health Sciences and Technologies-Interdepartmental Centre for Industrial Research (CIRI-SDV), University of Bologna, 40064, Ozzano dell'Emilia, Bologna, Italy.
Beatrice Mislei, AUB-INFA, National Institute of Artificial Insemination, University of Bologna, 40057, Cadriano, Italy.
Elisa Zironi, Department of Veterinary Medical Sciences, University of Bologna, 40064, Ozzano dell'Emilia. Bologna, Italy; Health Sciences and Technologies-Interdepartmental Centre for Industrial Research (CIRI-SDV), University of Bologna, 40064, Ozzano dell'Emilia, Bologna, Italy.
Gaetano Mari, Department of Veterinary Medical Sciences, University of Bologna, 40064, Ozzano dell'Emilia. Bologna, Italy; AUB-INFA, National Institute of Artificial Insemination, University of Bologna, 40057, Cadriano, Italy.

Document Type

Article

Publication Title

Theriogenology

Abstract

The objective of this investigation was to evaluate the pharmacokinetic parameters of tulathromycin in plasma and semen of beef bulls after administering a single sc dose at two different sites in the neck. Four Simmental bulls with excellent temperament received a comprehensive physical exam that included breeding soundness examination. In addition, blood was collected and analyzed for CBC and chemical panel in order to rule out any subclinical liver or kidney disease. All bulls were diagnosed as healthy and satisfactory potential breeders. The mean plasma levels of tulathromycin for the two neck sites of sc administration were not different between posterior aspect of the ear where it attaches to the head (RP; regio parotidea; 77.9 ± 43.3 ng/mL; X ± SD) and to the middle of the neck (RC; regio collis lateralis; 73.7 ± 39.7 ng/mL; P = 0.84). The mean seminal plasma levels of tulathromycin after administration in the RP was 608 ± 374 ng/mL and for RC was 867 ± 599 ng/mL without differences between both sites (P = 0.29). The mean level of tulathromycin in plasma was 75.8 ± 40.2 ng/mL, which was lower than mean seminal plasma levels of 781 ± 482 ng/mL (P = 0.001). The plasma peak tulathromycin concentration (C) was 160 ± 27 ng/mL at 21 ± 6 h (T) post-administration. The seminal plasma C was 1539 ± 44.4 ng/mL at 33.00 ± 18.00 h (T) post-administration. The C between plasma and seminal plasma were different (P = 0.008) without any differences in T between plasma and seminal plasma (P = 0.35). The terminal half-life for plasma tulathromycin (81.4 ± 27.6 h) showed a tendency to be shorter than in seminal plasma (114.7 ± 21.7; P = 0.10). The plasma area under the curve concentration time from the first to the last sample (AUC) was 15,440 ± 1717 ng/mL/h, which was significatively smaller compared with 171,071 ± 58,556 ng/mL/h for seminal plasma AUC (P = 0.01). The plasma means residence time from the first to the last sample (MRT) was 89.3 ± 5.1 h and it was shorter than for seminal plasma of 96.6 ± 5.0 h (P = 0.05). From the present investigation, it was concluded that tulathromycin is a suitable antibiotic based in its pharmacokinetic properties that could be used for treatment of bull genital infections when its application is indicated.

First Page

50

Last Page

55

DOI

10.1016/j.theriogenology.2021.09.019

Publication Date

1-1-2022

This document is currently not available here.

Share

COinS